Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
36.9 USD | +1.30% | +6.16% | +19.82% |
02:00pm | Collegium Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® and Nucynta® ER | CI |
04-11 | Collegium Pharmaceutical to Redeem $26.35 Million of Senior Notes | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company's profit outlook over the next few years is a strong asset.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+19.82% | 1.19B | C+ | ||
+25.76% | 661B | C+ | ||
+26.74% | 566B | B | ||
-6.64% | 352B | C+ | ||
+20.38% | 332B | B- | ||
+2.90% | 283B | C+ | ||
+13.55% | 231B | B+ | ||
+4.70% | 200B | B- | ||
-9.37% | 195B | A+ | ||
-5.22% | 145B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- COLL Stock
- Ratings Collegium Pharmaceutical, Inc.